CAD Therapeutics
CAD Therapeutics is a privately-held U.S.-based biotechnology company advancing an investigational, fixed-dose bupivacaine and clonidine formulation administered via stellate ganglion block. The company's primary focus is on addressing the physiological dimension of post-traumatic stress disorder (PTSD) through a pivotal Phase III candidate program, with expansion potential to other indications such as vasomotor symptoms. The development strategy utilizes a 505(b)(2) regulatory pathway and is supported by an issued and pending intellectual property estate.
Industries
N/A
Patents
Kits and methods for treating post traumatic stress disorder (PTSD) and hot flashes
2017-04-11 • US-9616054-B2
View DetailsKits and methods for treating post traumatic stress disorder (PTSD) and hot flashes
2017-03-28 • US-9603843-B2
View DetailsKits and methods for treating post traumatic stress disorder (PTSD) and hot flashes
2015-03-24 • US-8987327-B1
View Details
Kits and methods for treating post traumatic stress disorder (PTSD) and hot flashes
2017-04-11 • US-9616054-B2
View DetailsKits and methods for treating post traumatic stress disorder (PTSD) and hot flashes
2017-03-28 • US-9603843-B2
View DetailsKits and methods for treating post traumatic stress disorder (PTSD) and hot flashes
2015-03-24 • US-8987327-B1
View DetailsProducts
An investigational, patent-protected fixed-dose combination of bupivacaine and clonidine, formulated for administration via stellate ganglion block (SGB), intended for evaluation in post-traumatic stress disorder and other indications.
An investigational, patent-protected fixed-dose combination of bupivacaine and clonidine, formulated for administration via stellate ganglion block (SGB), intended for evaluation in post-traumatic stress disorder and other indications.
Expertise Areas
- Clinical trial management in neuropsychiatric disorders
- Combination drug formulation development
- Regulatory compliance for CNS drug development
- Intellectual property strategy in biopharma
Key Technologies
- Fixed-dose combination drug formulation
- Stellate ganglion block technique
- Alpha-2 adrenergic agonists
- cGMP pharmaceutical manufacturing
Key People
Founder & Board Member
Co-Founder & CEO; Board Member
Clinical Lead
Investigator; Principal Investigator (Planned PTSD Clinical Program)
Biostatistician / CAPS-5 Endpoint Analysis
Scientific Lead
Founder & Board Member
Co-Founder & CEO; Board Member
Clinical Lead
Investigator; Principal Investigator (Planned PTSD Clinical Program)
Biostatistician / CAPS-5 Endpoint Analysis
Scientific Lead
News & Updates
2008 case report launching SGB investigation for PTSD.
Theoretical framework linking NGF, sympathetic sprouting, and norepinephrine dysregulation to SGB's effect in PTSD.
Largest published case series at the time in a combat-related PTSD population.
Randomized controlled trial of stellate ganglion block for PTSD, not involving the current investigational formulation.
Largest published retrospective SGB cohort to date reporting symptom improvements; not involving investigational product.
Ongoing study using pre/post fMRI to assess SGB impact on amygdala and insula activity.
2008 case report launching SGB investigation for PTSD.
Theoretical framework linking NGF, sympathetic sprouting, and norepinephrine dysregulation to SGB's effect in PTSD.
Largest published case series at the time in a combat-related PTSD population.
Randomized controlled trial of stellate ganglion block for PTSD, not involving the current investigational formulation.
Largest published retrospective SGB cohort to date reporting symptom improvements; not involving investigational product.
Ongoing study using pre/post fMRI to assess SGB impact on amygdala and insula activity.